Business Context and Reporting Period
Estrella Immunopharma, Inc. filed this Form 8-K regarding a change in its independent registered public accounting firm. The reported event occurred on January 30, 2024. Estrella became the Company’s accounting predecessor following the September 29, 2023 business combination with TradeUP Merger Sub Inc. and TradeUP Acquisition Corp. The Company is headquartered in Emeryville, California, and its common stock and warrants trade on Nasdaq under ESLA and ESLAW.
Financial Metrics and Liquidity
This filing does not provide current revenue, profit, cash flow, margins, debt, cash balances, or liquidity figures.
Marcum LLP’s audit report on Estrella’s financial statements for the fiscal year ended June 30, 2023 included an explanatory paragraph expressing substantial doubt about Estrella’s ability to continue as a going concern. The report was not adverse, disclaimed, qualified, or modified regarding audit scope, accounting principles, or other uncertainties.
Material Changes Versus the Prior Comparable Period
- Effective January 30, 2024, the Board, following the Audit Committee’s recommendation, dismissed Marcum LLP.
- Effective the same date, the Company appointed Macias Gini & O’Connell, LLP as its independent registered public accounting firm for the fiscal year ending June 30, 2024.
- The Company reported no disagreements with Marcum regarding accounting principles, financial statement disclosure, or audit scope or procedures during the fiscal year ended June 30, 2023 or subsequent interim periods.
- The Company also reported no reportable events requiring disclosure under Item 304 of Regulation S-K.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing contains no operating or financial guidance.
- The principal disclosed risk is the substantial doubt regarding the accounting predecessor’s ability to continue as a going concern, as described in Marcum’s June 30, 2023 audit report.
- The filing states that neither the Company nor anyone acting on its behalf consulted MGO during the relevant periods regarding accounting treatment, audit opinions, disagreements, or reportable events.
- Marcum provided a letter dated February 1, 2024 regarding the Company’s disclosures; the letter is filed as Exhibit 16.1.
Investor Verification Items
- Review the June 30, 2023 financial statements and going-concern disclosures for the underlying causes of the substantial doubt.
- Confirm the scope and conclusions of MGO’s audit of the fiscal year ending June 30, 2024.
- Verify that no additional auditor disagreements, reportable events, or restatements arise in subsequent filings.
- Assess the Company’s cash needs, financing plans, and ability to fund operations, as this 8-K does not provide those details.